Correlation of progesterone levels on the day of oocyte retrieval with basal hormonal status and the outcome of ART

Tulić, Lidija; Tulić, Ivan; Bila, Jovan; Nikolic, Lj; Dotlić, Jelena; Lazarevic-Suntov, M; Kalezic, Ivana

doi:10.1038/s41598-020-79347-2

Cited by 8 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies reported progesterone monitoring in this category [57][58][59] . The progesterone threshold level used ranged from 2ng/ml to 12ng/ml.…”

Section: At Egg Collectionmentioning

confidence: 99%

“…One study 59 reported LBR at threshold level > 2ng/ml; one study 57 reported OPR at threshold level > 11.7ng/ml; three studies [57][58][59] reported CPR at different threshold levels > 2ng/ml, > 11.7ng/ml and > 12ng/ml; two studies 58,59 reported MR at threshold levels > 2ng/ml and > 12ng/ml. Data from single studies were summarised in Supplementary Table S3.…”

Section: At Egg Collectionmentioning

confidence: 99%

See 1 more Smart Citation

Progesterone level in assisted reproductive technology - a Systematic Review and Meta- analysis

Lim,

Hamdan,

Maheshwari

et al. 2024

Preprint

View full text Add to dashboard Cite

Currently, many measure progesterone in ART cycles as part of cycle monitoring. Elevated or inadequate progesterone levels during ART cycle monitoring may lead to cycle cancellations or further progesterone supplementation, but practice varies. It remains controversial if measuring progesterone improves clinical outcomes. This review aims to investigate if progesterone levels at different phases of fresh and frozen ART cycles influence pregnancy outcomes, in particular, that pertaining day 3 versus day 5 embryo transfers. A systematic search of EMBASE, MEDLINE, CINAHL and PubMed identified studies between 2000 and 2022. We included studies with women undergoing fresh and frozen IVF/ICSI cycles; with extractable per woman data on pregnancy outcomes where serum progesterone measurement was performed. We excluded studies with intervention or donor cycles. The primary outcome was LBR and the secondary outcomes were OPR, CPR and MR. Eligible studies were included after the initial screen of the titles and abstracts. PICOS study protocol was used. Analysis was done using RevMan5. The study was registered with PROSPERO (registration ID CRD42022382423). 64 studies (N = 57,988 women) were included. In fresh cycles, there is no evidence that elevated progesterone (EP) impacts live birth rate (LBR) at baseline (OR 0.76, 95% CI 0.39–1.49). EP at ovulation trigger is associated with a lower LBR for D3 (P > 1.0ng/ml, OR 0.46, 95% CI 0.38–0.55; P > 1.5ng/ml, OR 0.68, 95% CI 0.47–0.98) but not D5 embryo transfer (P > 1.5ng/ml, OR 0.96, 95% CI 0.81–1.14). In FET cycles, we were unable to meaningfully meta-analyse studies due to significant study heterogeneity. In controlled ovarian stimulation, EP at baseline did not impact on LBR; EP at ovulation trigger is associated with a lower LBR for D3 but not for D5 embryo transfer. In FET cycles, as the studies were heterogeneous, we were unable to combine the data in a meaningful way.

show abstract

“…Three studies reported progesterone monitoring in this category [57][58][59] . The progesterone threshold level used ranged from 2ng/ml to 12ng/ml.…”

Section: At Egg Collectionmentioning

confidence: 99%

Section: At Egg Collectionmentioning

confidence: 99%

Progesterone level in assisted reproductive technology - a Systematic Review and Meta- analysis

Lim,

Hamdan,

Maheshwari

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Serum levels of hormones (especially estradiol and progesterone) vary during COH and influence pregnancy outcome for patients treated with IVF-ET ( 53 , 107 , 108 ). According to the studies mentioned above ( 37 , 38 , 49 – 51 ), cell experiments and clinical data showed GDF-8 expression to be related to levels of estrogen and progesterone.…”

Section: Diagnostic Approaches and Potential Therapeuticmentioning

confidence: 99%

Regulatory Role and Potential Importance of GDF-8 in Ovarian Reproductive Activity

Zheng

Qin

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Growth differentiation factor-8 (GDF-8) is a member of the transforming growth factor-beta superfamily. Studies in vitro and in vivo have shown GDF-8 to be involved in the physiology and pathology of ovarian reproductive functions. In vitro experiments using a granulosa-cell model have demonstrated steroidogenesis, gonadotrophin responsiveness, glucose metabolism, cell proliferation as well as expression of lysyl oxidase and pentraxin 3 to be regulated by GDF-8 via the mothers against decapentaplegic homolog signaling pathway. Clinical data have shown that GDF-8 is expressed widely in the human ovary and has high expression in serum of obese women with polycystic ovary syndrome. GDF-8 expression in serum changes dynamically in patients undergoing controlled ovarian hyperstimulation. GDF-8 expression in serum and follicular fluid is correlated with the ovarian response and pregnancy outcome during in vitro fertilization. Blocking the GDF-8 signaling pathway is a potential therapeutic for ovarian hyperstimulation syndrome and ovulation disorders in polycystic ovary syndrome. GDF-8 has a regulatory role and potential importance in ovarian reproductive activity and may be involved in folliculogenesis, ovulation, and early embryo implantation.

show abstract

“…There is a broad consensus that the use of progesterone (Pg) is recommended for the luteal phase support in IVF [7,36,37,38]. Cochrane meta-analysis showed a higher LBR in patients receiving progesterone compared to those without it, with no differences in the applied doses or administration routes (vaginal, parenteral) [39].…”

Section: Luteal Phase Supportmentioning

confidence: 99%

Adjuvant therapy in assisted fertilization procedures

Bila

Spremović-Radjenović

2022

Srp Arh Celok Lek

View full text Add to dashboard Cite

Introduction. Despite continuous advances in assisted reproductive technologies (ART), their outcomes are limited. Before introducing adjuvant therapy to improve the in vitro fertilization (IVF) outcome, it is important to identify appropriate groups of patients, and avoid equal approach for everyone. Objective The objective of this paper was to review the available literature on the most commonly used adjuvant therapy aiming to improve the outcome of IVF. The guidelines of the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) were used, and the available literature was analyzed by searching the Medline-PubMed and Cochrane databases using appropriate keywords for each entity. Discussion. A review of the literature found no consistent evidences for the standard use of metformin in patients with polycystic ovarian syndrome (PCOSy), nor for use of dehydroepiandrosterone (DHEA), testosterone (T) and growth hormone (GH) in patients with premature ovarian failure or those with poor response to stimulation. The standard usage of prednisone and aspirin in the general population of patients in ART is also not recommended. Recently, the significance of the oxidative stress has been emphasized, which is why the use of antioxidants in the form of supplementation (Melatonin, vitamins C, A, E, Coenzyme Q) might be important in improving reproductive outcomes. Conclusion. The modern approach to the problem of infertility has become strictly individual. The application of adjuvant therapy in order to improve the outcome of ART procedures requires an analytical and critical approach in each individual case.

show abstract

Correlation of progesterone levels on the day of oocyte retrieval with basal hormonal status and the outcome of ART

Cited by 8 publications

References 41 publications

Progesterone level in assisted reproductive technology - a Systematic Review and Meta- analysis

Progesterone level in assisted reproductive technology - a Systematic Review and Meta- analysis

Regulatory Role and Potential Importance of GDF-8 in Ovarian Reproductive Activity

Adjuvant therapy in assisted fertilization procedures

Contact Info

Product

Resources

About